Association of IL1A gene polymorphisms with susceptibility to and severity of systemic sclerosis in the Japanese population

Arthritis and Rheumatism

Volumn 48, Issue 1, 2003, Pages 186-192

  Kawaguchi, Yasushi ^a   Tochimoto, Akiko ^a   Ichikawa, Naomi ^a   Harigai, Masayoshi ^a   Hara, Masako ^a   Kotake, Shigeru ^a   Kitamura, Yutaka ^b   Kamatani, Naoyuki ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b MITSUBISHI RESEARCH INSTITUTE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1ALPHA;

ADULT; AGED; ARTICLE; CHROMOSOME 2; DISEASE SEVERITY; FEMALE; FIBROBLAST; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HAPLOTYPE; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMIC SCLEROSIS;

5' FLANKING REGION; ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; EXONS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; INTERLEUKIN-1; JAPAN; MALE; MIDDLE AGED; PHENOTYPE; POLYMORPHISM, GENETIC; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX;

EID: 0037231514     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.10736     Document Type: Article

References (40)

1. Varga J, Jimenez SA. Pathogenesis of scleroderma: cellular aspects. In: Clements PJ, Furst DE, editors. Systemic sclerosis. Philadelphia: Williams & Wilkins; 1996. p. 123-52.
2. LeRoy EC. Increased collagen synthesis by scleroderma skin fibroblasts in vitro: a possible defect in the regulation or activation of the scleroderma fibroblasts. J Clin Invest 1974;54:880-9.
3. Feghali CA, Bost KL, Boulware DW, Levy LS. Mechanisms of pathogenesis in scleroderma. I. Overexpression of interleukin-6 by fibroblasts cultured from affected skin sites of patients with scleroderma. J Rheumatol 1992;19:1207-11.
4. Igarashi A, Nashiro K, Kikuchi K, Sato S, Ihn H, Grotendorst GR, et al. Significant correlation between connective tissue growth factor gene expression and skin sclerosis in tissue sections from patients with systemic sclerosis. J Invest Dermatol 1995;105:280-4.
5. Kawaguchi Y, Suzuki K, Hara M, Hidaka T, Ishizuka T, Kawagoe M, et al. Increased endothelin-1 production in fibroblasts derived from patients with systemic sclerosis. Ann Rheum Dis 1994;53: 506-10.
6. Kurasawa K, Hirose K, Sano H, Endo H, Shinkai H, Nawata Y, et al. Increased interleukin-17 production in patients with systemic sclerosis. Arthritis Rheum 2000;43:2455-63.
7. Ihn H, Yamane K, Kubo M, Tamaki K. Blockade of endogenous transforming growth factor β signaling prevents up-regulated collagen synthesis in scleroderma fibroblasts: association with increased expression of transforming growth factor β receptors. Arthritis Rheum 2001;44:474-80.
8. Kawaguchi Y. IL-1α gene expression and protein production by fibroblasts from patients with systemic sclerosis. Clin Exp Immunol 1994;97:445-50.
9. Kawaguchi Y, Hara M, Wright TM. Endogenous IL-1α from systemic sclerosis fibroblasts induces IL-6 and PDGF-A. J Clin Invest 1999;103:1253-60.
10. Higgins GC, Wu Y, Postlethwaite AE. Intracellular IL-1 receptor antagonist is elevated in human dermal fibroblasts that overexpress intracellular precursor IL-1α. J Immunol 1999;163:3969-75.
11. Takemura H, Suzuki H, Fujisawa H, Yuhara T, Akama T, Yamane K, et al. Enhanced interleukin 6 production by cultured fibroblasts from patients with systemic sclerosis in response to platelet derived growth factor. J Rheumatol 1998;25:1534-9.
12. Chizzolini C, Raschi E, Rezzonico R, Testoni C, Mallone R, Gabrielli A, et al. Autoantibodies to fibroblasts induce a proadhesive and proinflammatory fibroblast phenotype in patients with systemic sclerosis. Arthritis Rheum 2002;46:1602-13.
13. Kawaguchi Y, Nakamura H, McCarthy SA, Wright TM. Cultured dermal fibroblasts from systemic sclerosis patients exhibit constitutive nuclear and cytoplasmic expression of IL-1α [abstract]. Arthritis Rheum 1995;38 Suppl 9:S308.
14. Wessendorf JH, Garfinkel S, Zhan X, Brown S, Maciag T. Identification of a nuclear localization sequence within the structure of the human interleukin-1α precursor. J Biol Chem 1993; 268:22100-4.
15. McDowell TL, Symons JA, Ploski R, Førre Ø, Duff GW. A genetic association between juvenile rheumatoid arthritis and a novel interleukin-1α polymorphism. Arthritis Rheum 1995;38:221-8.
16. Loughlin J, Dowling B, Mustafa Z, Chapman K. Association of the interleukin-1 gene cluster on chromosome 2q13 with knee osteoarthritis. Arthritis Rheum 2002;46:1519-27.
17. Kornman KS, Crane A, Wang HY, di Giovine FS, Newman MG, Pirk FW, et al. The interleukin-1 genotype as a severity factor in adult periodontal disease. J Clin Periodontol 1997;24:72-7.
18. Rogers J. An IL-1 alpha susceptibility polymorphism in Alzheimer's disease: new fuel for the inflammation hypothesis. Neurology 2000;55:464-5.
19. Van den Velden PA, Reitsma PH. Amino acid dimorphism in IL1A is detectable by PCR amplification. Hum Mol Genet 1993; 2:1753.
20. Lang NP, Tonetti MS, Suter J, Sorrell J, Duff GW, Kornman KS. Effect of interleukin-1 gene polymorphisms on gingival inflammation assessed by bleeding on probing in a periodontal maintenance population. J Periodontal Res 2000;35:102-7.
21. Boiardi L, Salvarani C, Timms JM, Silvestri T, Macchioni PL, di Giovine FS. Interleukin-1 cluster and tumor necrosis factor-α gene polymorphisms in polymyalgia rheumatica. Clin Exp Rheumatol 2000;18:675-81.
22. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
23. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis): classification, subsets, and pathogenesis. J Rheumatol 1988;15:202-5.
24. Kitamura Y, Moriguchi M, Kaneko H, Morisaki H, Morisaki T, Toyama K, et al. Determination of probability distribution of diplotype configuration (diplotype distribution) for each subject from genotypic data using the EM algorithm. Ann Hum Genet 2002;66:183-93.
25. Steen VD, Medsger TA Jr. Improvement in skin thickening in systemic sclerosis associated with improved survival. Arthritis Rheum 2001;44:2828-35.
26. Clements PJ, Hurwitz EL, Wong WK, Seibold JR, Mayes M, White B, et al. Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trial. Arthritis Rheum 2000;43:2445-54.
27. Bolster MB, Silver RM. Assessment and management of scleroderma lung disease. Curr Opin Rheumatol 1999;11:508-13.
28. Medsger TA Jr, Silman AJ, Steen VD, Black CM, Akesson A, Bacon PA, et al. A disease severity scale for systemic sclerosis: development and testing. J Rheumatol 1999;26:2159-67.
29. White B, Moore WC, Wigley FM, Xiao HQ, Wise RA. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 2000;132:947-54.
30. Giacomelli R, Valentini G, Salsano F, Cipriani P, Sambo P, Letizia M, et al. Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis. J Rheumatol 2002;29:731-6.
31. Kuwana M, Kaburaki J, Arnett FC, Howard RF, Medsger TA Jr, Wright TM. Influence of ethnic background on clinical and serologic features in patients with systemic sclerosis and anti-DNA topoisomerase I antibody. Arthritis Rheum 1999;42:465-74.
32. Kawaguchi Y, Wright TM. IL-1α expression determines the fibrogenic phenotype of systemic sclerosis (SSc) fibroblasts [abstract]. Arthritis Rheum 1996;39 Suppl 9:S315.
33. Kobayashi Y, Yamamoto K, Saido T, Kawasaki H, Oppenheim JJ, Matsushima K. Identification of calcium-activated neutral protease as a processing enzyme of human interleukin 1α. Proc Natl Acad Sci U S A 1990;87:5548-52.
34. Cox A, Camp NJ, Nicklin MJ, di Giovine FS, Duff GW. An analysis of linkage disequilibrium in the interleukin-1 gene cluster, using a novel grouping method for multiallelic markers. Am J Hum Genet 1998;62:1180-8.
35. Arnett FC, Cho M, Chatterjee S, Aguilar MB, Reveille JD, Mayes MD. Familial occurrence frequencies and relative risks for systemic sclerosis (scleroderma) in three United States cohorts. Arthritis Rheum 2001;44:1359-62.
36. Johnson RW, Tew MB, Arnett FC. The genetics of systemic sclerosis. Curr Rheumatol Rep 2002;4:99-107.
37. Renzoni E, Lympany P, Sestini P, Pantelidis P, Wells A, Black C, et al. Distribution of novel polymorphisms of the interleukin-8 and CXC receptor 1 and 2 genes in systemic sclerosis and cryptogenic fibrosing alveolitis. Arthritis Rheum 2000;43:1633-40.
38. Takeuchi F, Nabeta H, Fussel M, Conrad K, Frank KH. Association of the TNFa13 microsatellite with systemic sclerosis in Japanese patients. Ann Rheum Dis 2000;59:293-6.
39. Pandey JP, Takeuchi F. TNF-α and TNF-β gene polymorphisms in systemic sclerosis. Hum Immunol 1999;60:1128-30.
40. Fatini C, Gensini F, Sticchi E, Battaglini B, Angotti C, Conforti ML, et al. High prevalence of polymorphisms of angiotensin-converting enzyme (I/D) and endothelial nitric oxide synthase (Glu298Asp) in patients with systemic sclerosis. Am J Med 2002;112:540-4.